Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹2,115 Cr revenue.
COGS 53.3%, employees 7.7%.
“Revised EBITDA growth guidance to 8% to 12% growth YoY in FY'26”
“eight to 12% EBITDA growth...This is stand alone guidance that we have”
“40% growth guidance that we had given earlier, we'll be able to exceed that...in the second half of this year, we will have substantial sales of the CDMO”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 10.5% | 10.5% |
| ROCE | 12.9%▼ | 13.8% |
| Net Margin | 11.9%▲ | 8.7% |
| EBITDA Margin | 23.0%▲ | 16.0% |
| Debt To Equity | 0.29x▲ | 0.21x |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | ₹1,801 Cr -14.9% | ₹2,115 Cr +14.2% | ₹1,853 Cr -4.8% | ₹1,945 Cr |
| Other Income | (₹0.33 Cr) ↓ Decline | ₹10 Cr +106.7% | ₹5 Cr +111.0% | ₹2 Cr |
| Total Income | ₹1,800 Cr -15.3% | ₹2,125 Cr +14.4% | ₹1,858 Cr -4.6% | ₹1,948 Cr |
| COGS | ₹831 Cr -26.4% | ₹1,128 Cr +10.5% | ₹1,021 Cr -12.7% | ₹1,170 Cr |
| ₹1,518 Cr -14.0% | ₹1,765 Cr +13.3% | ₹1,557 Cr -7.7% | ₹1,687 Cr | |
| Profit Before Tax | ₹279 Cr -22.6% | ₹361 Cr +20.0% | ₹300 Cr +15.2% | ₹261 Cr |
| Exceptional Items | (₹3 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| ₹68 Cr -23.1% | ₹88 Cr +5.6% | ₹84 Cr +24.2% | ₹67 Cr | |
| Net Profit | ₹214 Cr -21.5% | ₹272 Cr +25.6% | ₹217 Cr +12.1% | ₹193 Cr |
| Profit (Owners) | ₹214 Cr -21.3% | ₹272 Cr +25.9% | ₹216 Cr +11.9% | ₹193 Cr |
| Other Comprehensive Income | (₹6 Cr) +37.1% | (₹10 Cr) | (₹0.45 Cr) +86.9% | (₹3 Cr) |
| EPS | ₹23.65 | ₹30.06 | ₹23.88 | ₹21.35 |
| Diluted Shares | ₹9 Cr | ₹9 Cr | ₹9 Cr | ₹9 Cr |
| Profit Or Loss Of Associates | ₹2 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Chandrakant Vallabhaji Gogri has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) R...
Aarti Pharmalabs Limited has informed the Exchange about Copy of Newspaper Publication
Aarti Pharmalabs Limited has informed the Exchange about Investor Presentation
Aarti Pharmalabs Limited has informed the Exchange about Schedule of meet
Aarti Pharmalabs Limited has informed the Exchange about Schedule of meet
Aarti Pharmalabs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Aarti Pharmalabs Limited has informed the Exchange regarding 'Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015'.
Aarti Pharmalabs Limited has informed the Exchange about Transcript
Aarti Pharmalabs Limited has informed the Exchange about Clarification Regarding Delay in Disclosure of Event to the Exchange
Aarti Pharmalabs Limited has informed the Exchange about Copy of Newspaper Publication
Aarti Pharmalabs Limited has informed the Exchange about Link of Recording
Aarti Pharmalabs Limited has informed the Exchange regarding 'Corrigendum to Intimation of Record Datefor Dividend dated February 09, 2026'.
Aarti Pharmalabs Limited has informed the Exchange about Investor Presentation
Aarti Pharmalabs Limited has informed the Exchange regarding Allotment of 10457 Shares.
Aarti Pharmalabs Limited has informed the Exchange that Record date for the purpose of Dividend is 16-Feb-2026.